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CharacteristicsAbstract The genus Acinetobacter is a major cause of nosocomial infections; it is increasingly
being associated with various epidemics and has become a widespread concern in a variety of hos-
pitals worldwide. Multi-antibiotic resistant Acinetobacter baumannii, is now recognized to be of
great clinical significance. Numerous reports relay to the spread of A. baumannii in the hospital set-
tings which leads to enhanced nosocomial outbreaks associated with high death rates. However,
many other Acinetobacter spp. also can cause nosocomial infections. This review focused on the role
of Acinetobacter spp. as nosocomial pathogens in addition to their persistence, antimicrobial resis-
tance patterns and epidemiology.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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The discovery of the genus Acinetobacter occurred in 1911,
where Beijerinck identified a pathogen namedMicrococcus cal-
coaceticus from soil on a calcium acetate-mineral medium
(Dijkshoorn, 2008; Doughari et al., 2011). It has had several
names, becoming known as Acinetobacter in the 1950s
(Munoz-Price and Weinstein, 2008). Acinetobacter group were
previously insufficiently defined for a very long time and con-
fusedly classified into different genera e.g. Achromobacter ani-
tratus, Achromobacter mucosus, Alcaligenes haemolysans,
Cytophaga, Diplococcus mucosus, Bacterium anitratum, Herel-
leavaginicola, Lingelsheimia, Mimapolymorpha, M. calcoaceti-
cus, Moraxella lwoffii and Neisseria winogradskyi (Jung and
Park, 2015). The genus Acinetobacter (from the Greek akine-
tos, i.e., nonmotile), was originally suggested in 1954 by
Brisou and Prevot (1954) to distinguish the organisms based
on their motility in the tribe ‘‘Achromobactereae” and was
composed of non-pigmented Gram-negative saprophytic bac-
teria comprising both oxidase-negative and oxidase-positive
species (Brisou and Prevot, 1954; Jung and Park, 2015). In
1957, Brisou identified a typical species named Acinetobacter
anitratum (Brisou, 1957; Jung and Park, 2015). In 1974,
Bergy’s Manual of Bacteriology placed these bacteria in thePlease cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.02.009family Neisseriaceae with only Acinetobacter calcoaceticus as
a species and the two subspecies A. anitratum and Acinetobac-
ter lwoffii, based on the observation that Acinetobacter has
the potential to acidify glucose (Doughari et al., 2011;
Balachandran et al., 2015). In the literature, the species
A. calcoaceticus has been divided into two subspecies. Anitratus
and A. calcoaceticus bv. lwoffii, based on similar characteristics
(Peleg et al., 2008).
2. Morphological and physiological characteristics
Acinetobacter spp. are short, plump, typically 1.0–1.5 lm by
1.5–2.5 lm in size as measured during the rapid phase of their
growth but often develop into more coccoid in the stationary
phase, usually present in pairs or long chains of variable length
(Jung and Park, 2015). Acinetobacter spp. are non-fastidious
and can be easily grown on regular laboratory media. On
blood agar plates, colonies display typical shapes and size,
being colorless (white or cream colored), smooth, or mucoid
(when capsule is present), milky, 1–2 mm in diameter (after
18–24 h incubation at 37 C), whereas colonies display bluish
to bluish gray color on eosin methylene blue agar. On Herellea
agar, the colonies are pale lavender in color, while on Leeds
Acinetobacter medium, the colonies are pink on a purplel pathogens: Epidemiology and resistance features. Saudi Journal of Biological
Acinetobacter spp. as nosocomial pathogens 3background (Doughari et al., 2011). Characteristic of colonies
on MacConkey agar are light lavender color indicating non-
lactose ferments. The genus Acinetobacter comprises species
that are strictly aerobic, non-motile, catalase-positive, indole-
negative, oxidase-negative, Gram-negative, and citrate positive
(Kurcik-Trajkovska, 2009) with G + C content of 39–47%
(Peleg et al., 2008). They are non-glucose-fermenting encapsu-
lated cocco-bacilli rods which prevail in fluid media, particu-
larly during the early stages of growth (Kurcik-Trajkovska,
2009). Many strains are unable to reduce nitrates to nitrites
and the optimum temperature is 33–35 C (Doughari et al.,
2011). The cell wall of Acinetobacter is typical of that of Gram
negative bacteria, however de-staining is difficult because it
keeps the crystal violet and this can lead to erroneous detection
as Gram-positive cocci.
3. Current taxonomy
The species’ names have endured substantial taxonomic
changes over the years due to the advanced understanding of
molecular methods of the genetic make-up of this group of
microorganisms. Recent classifications which seem to have
gained wide acceptance among bacterial taxonomists have
accepted this group of bacteria as gamma Proteobacteria
categorized in the order Pseudomonadales and the family
Moraxellaceae. Thus the taxonomical classification is given
as; Domain: Bacteria, Phylum: Proteobacteria, Class:
Gamma Proteobacteria, Order: Pseudomonadales, Family:
Moraxellaceae, Genus: Acinetobacter. The species
A. baumannii, Acinetobacter haemolyticus and A. calcoaceticus
are of clinical significance (Jung and Park, 2015).
4. Natural habitats for A. baumannii
Acinetobacter is a heterogeneous group of organisms that are
typically free living saprophytes, found almost everywhere,
commonly distributed in the environment. However, different
species of the genus are generally associated with various habi-
tats e.g. soil, water, sewage, human, foods and animals
(Kurcik-Trajkovska, 2009; Doughari et al., 2011; Jung and
Park, 2015).
Acinetobacter spp. are generally considered a part of the
normal flora of the skin (Towner, 2006), mucous membranes
or the pharynx, and human respiratory secretions (Munoz-
Price and Weinstein, 2008) and are accountable for a wide
variety of local and systemic infections, including pneumonia,
septicemia and wound infections (Beggs et al., 2006). The main
body areas populated by these microorganisms in hospitalized
patients are the skin, oropharynx, and digestive tract (Jung
and Park, 2015). In a study conducted by Seifert et al.
(1997), Acinetobacter spp. were isolated from various locations
of the healthy individuals’ body including the forehead, nose,
ear, throat, trachea, conjunctiva, hand, vagina and perineum,
inhabiting humid areas, such as axillae, the groin and toe webs
(Seifert et al., 1997).
Acinetobacter spp. have frequently been isolated from ani-
mals including birds; fish and rainbow trout (Peleg et al.,
2008; Kanafani and Kanj, 2014). They have also found that
food is also known to inhabit A. baumannii species. It has been
identified in a variety of food items, such as raw vegetables,
fruits, milk and dairy products (Kanafani and Kanj, 2014).Please cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.02.009Acinetobacter spp. can endure dry conditions for long peri-
ods thus A. baumannii is frequently isolated from reusable
medical equipments such as ventilator tubing, arterial pressure
monitoring devices, humidifiers, washbasins, plastic urinals
and respirometers (Kanafani and Kanj, 2014). They have also
been isolated from the skin of healthcare personnel, mat-
tresses, pillows and in all types of ventilator equipment and
moist situations (Beggs et al., 2006; Kanafani and Kanj, 2014).
5. Survival under harshest conditions and resistance to
desiccation
A. baumannii has the ability to survive on dry surfaces under
nutrient limiting conditions facilitates their persistence and
transmission in natural and medical environment. Further-
more, colonized medical devices and equipment could serve
as reservoirs in prolonged hospital outbreaks (Kanafani and
Kanj, 2014). Majority of A. baumannii strains persist longer
than Escherichia coli on dry surfaces; some of them can even
remain viable for more than 4 months. Additionally, A. bau-
mannii survived for more than 20 days on glass surfaces while
placed at room temperature and persisted on both moist and
dry surfaces. This characteristic enables the organism to sur-
vive in hospitals to spread infections. In fact, the soldiers’
infections by Acinetobacter were not acquired from the envi-
ronment but during their admission to medical facilities (Lee
et al., 2011; Kanafani and Kanj, 2014). Acinetobacter spp.
are more frequently found on inanimate objects and hands
of staff in the ICU than Staphylococcus aureus and Pseu-
domonas spp. It is hard to determine the significance of recov-
ery of Acinetobacter spp. from clinical materials, since they are
frequently colonized instead of infected (Lee et al., 2011;
Kanafani and Kanj, 2014).
6. Virulence factors of Acinetobacter
Acinetobacter is considered to be an organism of low virulence
(Kurcik-Trajkovska, 2009; Kanafani and Kanj, 2014). The
possible virulence factors are: cell surface hydrophobicity,
outer membrane proteins (OMPs), toxic slime polysaccharides
and verotoxins. Acinetobacter spp. has been demonstrated to
exhibit cell surface hydrophobicity, an important determinant
bacterial adhesion and which may also help it avoid being
phagocytosed (Kurcik-Trajkovska, 2009; Doughari et al.,
2011; Kanafani and Kanj, 2014). Several OMPs belonging to
the OmpA family have been characterized in different Acineto-
bacter strains. Outer membrane proteins (OMPs), that are pre-
sent in some Gram-negative bacteria, are known to have
crucial roles in pathogenesis and adaptation in host cells as
well as in antibiotic resistance (Doughari et al., 2011;
Kanafani and Kanj, 2014). A. baumannii lipopolysaccharides
(endotoxins) are potent stimulators of circulating white blood
cells to release pro-inflammatory substances (Erridge et al.,
2007; Kanafani and Kanj, 2014). They are toxic to neutrophils,
and inhibit their migration as well as their phagocytosis
(Kurcik-Trajkovska, 2009; Doughari et al., 2011; Kanafani
and Kanj, 2014). A. baumannii produce many factors like
extracellular enzymes, cytotoxins and secreted vascular perme-
ability that play a significant role in the pathogenesis and cause
harm to host tissues especially in respiratory tract infection
(Tomaras et al., 2008; Kanafani and Kanj, 2014). Otherl pathogens: Epidemiology and resistance features. Saudi Journal of Biological
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esterases, certain amino-peptidases, and acid phosphatases
(Doughari et al., 2011; Kanafani and Kanj, 2014). Vero-
toxins can be classified into two antigenic groups, vtx-1 and
vtx-2. The mechanism by which A. haemolyticus produces
the toxin is not well understood. The toxins belong to a partic-
ular protein subfamily, the RNA N-glycosidases which directly
target the cell ribosome machinery, inhibiting protein synthesis
(Lambert et al., 1993; Kanafani and Kanj, 2014).
7. Infections with A. baumannii
Most infections with A. baumannii involve organ systems that
contain high levels of fluids. Such systems include among
others the urinary and respiratory tract, peritoneal cavity,
and are linked to indwelling devices. The difference between
the infection and colonization with A. baumannii is difficult
to differentiate. It is believed that the retrieval of A. baumannii
in the hospitalized patient is a sign of severe illness, with a
related mortality of about 30% (Jung and Park, 2015).
7.1. Hospital-acquired Acinetobacter pneumonia
The majority of A. baumannii pathogens are isolated from the
respiratory tracts of hospitalized patients and it is very difficult
to differentiate between upper airway colonization from true
pneumonia. The incidence of this microorganism varies from
one site to another. However, it is the second most common
etiologic agent among all the Gram-negative bacteria (Luna
and Aruj, 2007). Nosocomial pneumonia occurs in intensive
care units (ICUs) with a frequency of 3–5% and with crude
death rates of 30–75% being reported (Doughari et al., 2011).
7.2. Community-acquired Acinetobacter pneumonia
Acinetobacter easily inhabit tracheostomy sites and result in
community acquired bronchiolitis and tracheobronchitis in
healthy children and in immuno-compromised adults but
rarely cause community-acquired pneumonia and sepsis
(Whitman et al., 2008). However, community-acquired pneu-
monia due to A. baumannii has been identified in tropical
regions of Australia and Asia during the rainy season in people
who have a history of alcohol abuse or have chronic obstruc-
tive pulmonary disease (Peleg et al., 2008; Whitman et al.,
2008).
7.3. Bacteremia (blood stream infection)
Bacteremia by A. baumannii is most commonly caused by
intravascular and respiratory tract catheter. The origin from
surgical wounds, burns and the urinary tract is less encoun-
tered and is infrequent from endocarditis. The origin of the
bacteremia is unknown in about 21–70% of the episodes
(Cisneros and Rodriguez-Bano, 2002).
In United States study (1995–2002), A. baumannii uses
1.3% of all the nosocomial bloodstream infections (0.6 blood-
stream infection/10,000 admissions). Moreover, A. baumannii
initiated more ICU-acquired bloodstream infection when com-
pared to non-ICU-ward infection (Cisneros and Rodriguez-
Bano, 2002; Garnacho-Montero et al., 2015). The overall
death rate from A. baumannii blood stream infections rangedPlease cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.02.009from 34.0% to 43.4% at the ICU and 16.3% outside the
ICU (Peleg et al., 2008; Garnacho-Montero et al., 2015).
7.4. Trauma and other wound infection
A. baumannii can be the cause of skin/soft tissue infections out-
side of the military population; it led to 2.1% of ICU-acquired
skin/soft tissue infections. Moreover, A. baumannii isolated
from combat casualties in Iraq or Afghanistan was the most
frequently isolated organism (32.5% of cases) from battle vic-
tims with open tibia fractures (Falagas et al., 2015).
7.5. Urinary tract infection
A. baumannii is an infrequent cause of UTI; according to one
study, it is responsible for only 1.6% of ICU-acquired UTIs.
This organism is usually linked to catheter-associated infection
or colonization. It is unusual for A. baumannii to cause compli-
cated UTI in outpatients (Peleg et al., 2008; Falagas et al.,
2015).
7.6. Meningitis
Nosocomial post neurosurgical meningitis, caused by
multidrug-resistant A. baumannii, is an increasingly important
issue (Doughari et al., 2011; Basri et al., 2015). In a number of
acute bacterial meningitis in adults, Acinetobacter was respon-
sible for around 10% of Gram-negative bacillary and 4% of all
nosocomial meningitides. Mortality may be as high as 70%,
although its cause is often hard to discern (Peleg et al., 2008;
Basri et al., 2015).
7.7. Other manifestations
A small number of reported cases of A. baumannii endocarditis
exist. The majority of these cases involved prosthetic valves. A.
baumannii may cause endocarditis, peritonitis, ophthalmitis or
keratitis associated with contact lens use or following eye sur-
gery (Bergogne-Berezin and Towner, 1996; Peleg et al., 2008).
8. Epidemiology of A. baumannii
A. baumannii is primarily a healthcare-associated pathogen
and many reports indicated it as the cause of outbreaks and
nosocomial infections including septicemia, bacteremia,
ventilator-associated pneumonia, wound sepsis, endocarditis,
meningitis, and urinary tract infections (Vashist et al., 2011).
MDR Acinetobacter only poses a minimal threat to healthcare
workers or patients’ family members since it rarely causes any
serious infection in healthy people. Outbreaks are frequently
encountered in intensive-care and burn units which involve
patients on mechanical ventilation www.hopkinsmedicine.
org/heic/ID/mdr (Kanafani and Kanj, 2014).
8.1. Global epidemiology of A. baumannii
A. baumannii is commonly found in water and soil (Kanafani
and Kanj, 2014) in addition to many health care environments,
causing human colonizer in the hospital (Villegas and
Hartstein, 2003). Several epidemiology studies have reportedl pathogens: Epidemiology and resistance features. Saudi Journal of Biological
Acinetobacter spp. as nosocomial pathogens 5the occurrence of MDR A. baumannii infections in different
regions of the world including Europe, North America, Argen-
tina, Brazil, China, Taiwan, Hong Kong, Japan, and Korea
(Kanafani and Kanj, 2014) and often associated with nosoco-
mial infections. Community acquired pneumonia have been
reported in tropical regions of the world especially during
warm and humid months (Doughari et al., 2011; Kanafani
and Kanj, 2014). United Kingdom and US military detected
an escalation in the number of highly resistant isolates of
Acinetobacter baumannii calcoaceticus complex among military
personnel who were wounded while deployed to Iraq and
Afghanistan (Peleg et al., 2008).
8.2. Middle East epidemiology of A. baumannii
Several cases of MDR A. baumannii have been reported from
hospitals in the United Arab Emirates, Bahrain, Saudi Arabia,
Palestine and Lebanon (Mugnier et al., 2008;Mugnier et al.,
2009). A retrospective study to evaluate the prevalence of mul-
tidrug resistant bacteria that causes infections in patients at the
intensive care units (ICUs) of Riyadh Military Hospital, Saudi
Arabia, showed that most common types of bacteria isolated
from intensive care patients were A. baumannii, which repre-
sent 40.9% of the samples (Saeed et al., 2010). In another ret-
rospective study in an adult ICU tertiary care Hospital in
Riyadh, Saudi Arabia, showed that most frequently isolated
organism was A. baumannii (Kamolvit et al., 2015).
8.3. Epidemiology of outbreaks
One important feature of A. baumannii is its tendency to cause
outbreaks due to its resistant antimicrobial agents and its abil-
ity to overcome desiccation (Fournier et al., 2006). Specific
resistant clones are the predominant cause of outbreaks and
three European clones (designated as I, II and III) have dis-
seminated in geographically distinct areas and in specific insti-
tutional outbreaks, the majority of A. baumannii isolates
usually belong to a single clone (Karageorgopoulos and
Falagas, 2008; Zowawi et al., 2015).
9. Modes of transmission
9.1. Environmental contamination
Environmental sites that are most likely to be colonized are
those in the vicinity of affected patients, for example, fomites
such as feather pillows, bed linen, surrounding curtains, along
with bedrails, bedside tables, water used for nasogastric feed-
ing or ventilator rinsing and gas taps behind the beds in addi-
tion to door handles, computer keyboards, sinks, and/or even
cleaning equipment (Karageorgopoulos and Falagas, 2008).
Contamination of hospital equipment from the hospital envi-
ronment with Acinetobacter outbreaks has been often identi-
fied, ranging from suctioning equipment to pillows and
mattresses and most reports refer to respiratory equipment
used for mechanical ventilation, suctioning, devices related to
intravascular access (Karageorgopoulos and Falagas, 2008;
Jung and Park, 2015). Moreover, in a study done in Nether-
lands, both A. baumannii and genomic species 13 were shown
to be the source of contamination of feather pillows that werePlease cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
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Kanj, 2014). Also, wet mattresses have been identified to be
the reservoir of infection and reported an A. calcoaceticus out-
break in a burn unit (Sherertz and Sullivan, 1985; Ebringer,
2015).
9.2. Air-borne transmission and aerial dissemination
Concerning the epidemiology of healthcare-associated infec-
tion, only little light has been shed on the importance of air-
borne route of transmission although there is an increasing
evidence that may be a mode of transmission of major
Gram-negative bacteria pathogens, such as Pseudomonas
aeruginosa and Acinetobacter spp. Weernink et al. (1995) inves-
tigated the airborne diffusion of Acinetobacter spp. from
patient’s pillows using settle plates; they found aerial dispersal
of this microorganism from feather pillows, but not from syn-
thetic pillows. Another proof of the airborne dissemination of
Acinetobacter spp. was shown in a study in Hong Kong
(Houang et al., 2001). Moreover, in a Danish study, Gerner-
Smidt (1987) used both settle plates and a slit sampler to
recover an outbreak of strain A. calcoaceticus subsp. Anitratus
from the air in an ICU (Gerner-Smidt, 1987; Townsend et al.,
2015).
9.3. Hand of stuff
The hands of healthcare personnel can be colonized with A.
baumannii outbreak strains, thus facilitating spread to patients
(Karageorgopoulos and Falagas, 2008). Health-care workers
with damaged skin are at increased risk of developing hand
colonization with A. baumannii. Epidemiological studies
demonstrate that hand-carriage rates among nurses and physi-
cians varied between 3% and 23% and was usually transient,
except in the case of injured skin (Cisneros and Rodriguez-
Bano, 2002; Townsend et al., 2015).
10. Colonized patient
The potential modes of A. baumannii transmission into a
ward are displayed through a colonized patient being the
most likely mode. After its diffusion to a ward, A. baumannii
can be transmitted from the colonized patient to the sur-
roundings and to other susceptible patients. Transfer of
Acinetobacter to several patients is boosted by a combination
of multiple-site patient colonization, widespread environmen-
tal contamination, persistence on dry surfaces and hands for
long periods, and the ability to develop or gain resistance to
nearly all classes of antimicrobial agents (Villegas and
Hartstein, 2003). The presence of colonized patients leads
to maintaining the persistence of multidrug-resistant A. bau-
mannii species in the health care setting (Eliopoulos et al.,
2008). Cross-transmission and diffusion from the hospital
environment are more likely than endogenous sources to be
the source of infecting or colonizing organisms in nosocomial
infections (Luna and Aruj, 2007; Kanafani and Kanj, 2014).
A strategy of weekly pharyngeal and rectal swab cultures in
73 patients newly admitted in an ICU identified 46 (96%)
of 48 patients who became colonized with A. baumannii
(Karageorgopoulos and Falagas, 2008).l pathogens: Epidemiology and resistance features. Saudi Journal of Biological
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It is generally agreed that A. baumannii is the most medically
significant Acinetobacter spp. The clinical impact of the Acine-
tobacter was increasing morbidity or mortality and their infec-
tions are responsible for the increase in patient mortality that
occurs in critically ill patients (Doughari et al., 2011). It is con-
sidered as a low virulence organism except when isolated in
critically ill or immuno-compromised patients. These organ-
isms are most often associated with nosocomially rather than
community-acquired infections (Jain and Danziger, 2004;
Islahi et al., 2015). The ability of A. baumannii to develop mul-
tidrug resistance and to persist in harsh environmental condi-
tions makes infections by Acinetobacter very dangerous
specially in individuals who have recently undergone major
surgery, have malignant diseases or burns or immuno-
suppressed patients such as the elderly, neonates with low birth
weights, and patients with prolonged illnesses (Doughari et al.,
2011; Kanafani and Kanj, 2014). Patients with mechanical
ventilation, particularly of prolonged duration, longer hospital
or ICU stay, greater degree of exposure to infected or colo-
nized patients in the neighboring hospital environment have
an increasing risk for the acquisition of multidrug-resistant
outbreak strains (Kanafani and Kanj, 2014).
12. Multidrug resistant A. baumannii
For the past 30 years, strains of A. baumannii have acquired
resistance to newly developed antimicrobial drugs; these
strains are known as MDR A. baumannii. It became prevalent
in many hospitals all over the world and has been recently rec-
ognized there as a leading nosocomial pathogen (Abbo et al.,
2005; Kanafani and Kanj, 2014). Different terminology like
multidrug resistant (MDR), extensive drug resistant (XDR),
and pan-drug resistant (PDR) have been used with various def-
initions to describe the degree of antimicrobial resistance for
Acinetobacter spp. MDR Acinetobacter spp. can refer to being
resistant to a minimum of three classes of antimicrobial drugs
e.g. all penicillins and cephalosporins fluoroquinolones, and
aminoglycosides (Jung and Park, 2015). Another specific defi-
nition of multidrug resistance is whenever there is resistance to
more than two of the following five drug classes: anti-
pseudomonal cephalosporins (ceftazidime or cefepime), anti-
pseudomonal carbapenems (imipenem or meropenem),
ampicillin-sulbactam, fluoroquinolones (ciprofloxacin or levo-
floxacin), and aminoglycosides (gentamicin, tobramycin, or
amikacin) (Peleg et al., 2008; Guide, 2010; Kanafani and
Kanj, 2014).
MDR Acinetobacter strains which show additional resistant
to carbapenems will be defined as XDR. Finally, PDR Acine-
tobacter spp. is a term given to the XDR Acinetobacter spp.
that is also resistant to polymyxins and tigecycline. These cat-
egorizations help to define the extent of resistance and rational
antimicrobial therapy in a clear way (Manchanda et al., 2010).
12.1. Genetics of resistance in Acinetobacter
Acinetobacter spp. are well suited for genetic exchange and
belong to a unique class of Gram-negative bacteria labeled
as ‘‘naturally transformable”. This remarkable capacity forPlease cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
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resistance genes is possible (Gallagher et al., 2015). The major
types of gene transfer among A. baumannii are:
12.1.1. Transformation
In 1969, Juni and Janik (1969) discovered a hyper trans-
formable Acinetobacter strain, i.e. a strain able to take up
DNA from lysed bacterial cells and able to recombine this
DNA into its genome, and designated this strain as ‘‘A. cal-
coaceticus”. Moreover, Juni and Janik (1969) showed that this
strain could be transformed by DNA-extracts prepared from
265 bacterial strains belonging to eleven different genera,
and that in fact these strains were close genetic relatives, all
belonging to the genus Acinetobacter (Utnes et al., 2015).
12.1.2. Conjugation
The first description of conjugation was reported in 1976 in an
A. calcoaceticus strain. The vector used for conjugation was
abroad-host-range plasmid RP4 and was able to mobilize
chromosomal genes between different A. calcoaceticus
mutants. Chromosomal transfer by conjugation has also been
reported with the naturally occurring Acinetobacter plasmid
pAV1 (Yang et al., 2015).
12.1.3. Transduction
Several bacteriophages which are active against particular
strains of Acinetobacter have been isolated. Although most
of them are lytic phages, temperate phage P78 lysogenizes its
host strain (Utnes et al., 2015). Nevertheless, this phage is
specific for its host strain and cannot be used for genetic stud-
ies in Acinetobacter spp.
12.1.4. Mobile genetic elements
Members of the genus Acinetobacter have a tendency to
quickly develop resistance to the antimicrobial agents. They
are intrinsically resistant to many antibiotics and have a great
ability to acquire new resistance mechanisms. More than
25 years ago, Fournier et al. (2006) demonstrated that A. bau-
mannii plasmids, transposons and integrons are generally
major contributing factors in the acquisition and transfer of
these mechanisms of resistance. The presence of class I and
class II integrons in A. baumannii has been considerably linked
to multiple antibiotic resistances and the nosocomial propaga-
tion of isolates has been illustrated in both environmental and
clinical strains of A. baumannii worldwide (Fournier et al.,
2006). A large number of Acinetobacter clinical isolates have
integrons incorporated into their chromosome. The presence
of these mobile elements in epidemic strains, possibly because
most of the cassettes identified are associated with antibiotic
resistance. Indeed, it has been implied that integrons con-
tribute significantly to the diffusion of antibiotic resistance
genes (Perez et al., 2007; Gheorghe et al., 2015). In A. bauman-
nii, the (insertion sequences, IS) IS elements act as strong pro-
moters of the production of b-lactamase and have a role to
acquire other resistant phenotypes (Perez et al., 2007;
Gheorghe et al., 2015). Fournier et al. (2006) described about
86 kb Resistance Island in the epidemical MDR A. baumannii
strain AYE, which contained 45 of the 52 resistant genes. In
the same position, in the susceptible A. baumannii strain
SDF, there was a 20 kb genomic island that did not containl pathogens: Epidemiology and resistance features. Saudi Journal of Biological
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mannii ATCC 17978 was sequenced and 28 putative alien
islands have identified, 16 of them contained genes directly
implicated in virulence (Smith et al., 2007; Gheorghe et al.,
2015).
12.2. Mechanisms of antibiotic resistance
The mechanisms of antimicrobial resistance in A. baumannii
are generally classified into five broad categories (Kamolvit
et al., 2015).
12.2.1. Antimicrobial-inactivating enzymes
Enzymatic degradation by b-lactamases is the most prevailing
mechanism of b-lactam resistance in A. baumannii.
b-lactamases are divided into 4 molecular groups: Ambler class
A, Ambler class B (metallo enzymes), Class C b-lactamases,
and Ambler class D (oxacillinases). These enzymes, at least
partially, hydrolyze carbapenems along with other b-lactams
(Jain and Danziger, 2004). Extended-spectrum b-lactamases
(ESBLs) from the Ambler class A group have been described
for A. baumannii. Many ESBLs were identified in A. baumannii
including TEM-92 and 116 from Italy and Netherlands respec-
tively, and SHV-12 from China and the Netherlands. In addi-
tion, CTX-M-2 and CTX-M-43 have been reported from
Japan and Bolivia correspondingly. Further attention is being
currently given to VEB-1, which circulated throughout hospi-
tals in France (clonal dissemination) and was also recently
encountered in Belgium and Argentina (VEB-1a), PER-1,
from France, Turkey, Belgium, Romania, Korea, and United
States and PER-2 from Argentina. Narrow-spectrum
b-lactamases, such as TEM-1 and TEM-2, are also predomi-
nant in A. baumannii but their clinical importance is restricted
due to the strength of other resistance factors (Jain and
Danziger, 2004).
Ambler class B is an acquired resistance mechanism that is
located on the chromosome or plasmids that hydrolyze all
b-lactam antibiotics except aztreonam. There is a distinguish-
ing metal ion in the active site, usually zinc, which aids in catal-
ysis and differentiates it from class A and D carbapenemases
(Perez et al., 2007). Two major metallo-b-lactamases have
been reported in A. baumannii: ‘‘Verona integron-encoded
metallo-b-lactamases” (VIM) and ‘‘Imipenem hydrolyzing
b-lactamase” (IMP). IMP or VIM family has been described
in various areas in the world, including Japan, Italy,
Hong Kong, and Korea (Perez et al., 2007). Since MBLs are
usually situated on mobile genetic elements easily transmitted
among bacteria, they are considered to pose a significant threat
(Urban et al., 2003).
A. baumannii characteristically produces an AmpC-type
cephalosporinase recognized as Acinetobacter-derived
cephalosporinases (ADCs) (Manchanda et al., 2010). These
enzymes do not decrease the efficiency of expanded spectrum
cephalosporins when expressed at a basal level. ADCs hydro-
lyze the antibiotic penicillins and extended spectrum
cephalosporins.
The presence of an upstream insertion sequence (IS) ele-
ment known as ISAba1or (bla genes code for class C
cephalosporinases) is the main determinant regulating over
expression of AmpC enzyme in A. baumannii. Cefepime and
carbapenems seem to be resistant to the hydrolysis initiatedPlease cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
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about 28 bla ADC genes have been found and are listed in Gen-
Bank (Perez et al., 2007).
Class D (OXA) carbapenemases, another naturally occur-
ring b-lactamase in A. baumannii, is the leading cause of car-
bapenem resistance in this microorganism (Manchanda et al.,
2010). These were described in regions such as Scotland, Spain,
France, Japan, Singapore, China, Brazil, Cuba, and Kuwait
(Manchanda et al., 2010). Four groups of the Class D
carbapenem-hydrolyzing enzymes CHDLs, including OXA-
23-like, OXA-24-like, OXA-58-like, and OXA-51-like
enzymes, have been identified in A. baumannii. Emergence
and extensive diffusion of OXA 23, 24/40, and 58 car-
bapenemases among Acinetobacter spp. have been reported
in Asia-Pacific countries.
OXA-23 was the first example of such an OXA carbapene-
mase in A. baumannii. It was detected in 1985, in a clinical iso-
late in Scotland before the introduction of carbapenems. Since
then, the initially termed ARI-1 (Acinetobacter resistant to imi-
penem), which is a plasmid-encoded enzyme, has been
reported in England, Brazil, Polynesia, Singapore, Korea,
and China (Manchanda et al., 2010).
12.2.2. Changes in OMPs
Understanding the involvement of porins or outer membrane
proteins (OMPs) to antimicrobial resistance in A. baumannii
has been a challenge. One report suggested that reduced
expression or mutation in porins may be associated with car-
bapenem resistance. Carbapenem resistance in Acinetobacter
spp. has been associated to the loss of proteins through porin
channels from the outer membrane. It is possible that b-
lactamases and outer-membrane changes work together to
grant resistance to b-lactam agents (Manchanda et al., 2010).
The loss of CarO, a 29-kDa protein, was recently proven to
be related to imipenem and meropenem resistance, showing
that this porin creates nonspecific channels. Another protein,
Omp25, was identified in relation to CarO, but it lacked
pore-forming ability. The carO gene disruption by distinct
insertion elements leads to loss of the CarOporin in
imipenem-resistant A. baumannii.
Detected clinical outbreaks of carbapenem-resistant A. bau-
mannii due to porin loss, that included reduced expression of a
number of OMPs such as 47, 44, and 37 kDa OMPs in A. bau-
mannii strains endemic in New York City in addition to
reduced expression of 22 kDa and 33 kDa OMPs in associa-
tion with OXA-24 in Spain (Bonomo and Szabo, 2006).
Heat-modifiable protein HMP-AB, a 33-36-kDa and 43 kDa
proteins are also identified OMPs involved in b-lactam resis-
tance (Jain and Danziger, 2004).
12.2.3. Efflux pumps
Efflux pumps usually have 3 components, including the pump
itself, present in the cytoplasmic membrane; an exit portal
(porin channels that pass through the outer membrane) and
a linker lipoprotein between the two. Resistance-nodulation-
division (RND) type efflux pump has been illustrated in A.
baumannii and is responsible for aminoglycoside, quinolones,
tetracyclines, chloramphenicol, erythromycin, trimethoprim,
and ethidium bromide resistance (Nowak et al., 2015). AbeM,
which is another multidrug efflux pump from A. baumannii,
has been newly identified and described as an element of thel pathogens: Epidemiology and resistance features. Saudi Journal of Biological
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strates appears to be restricted to fluoroquinolones, among
other toxic compounds (Perez et al., 2007). An expansive range
of multidrug efflux systems is encoded by the genome of a
multidrug-resistant A. baumannii strain. The (RND) family-
type pump AdeABC is the most studied so far and it has a sub-
strate profile that includes b-lactams (including carbapenems)
and other antimicrobials. Similarly to other RND-type pumps,
AdeABC has a three-component structure: AdeB creates the
trans membrane component, AdeA forms the inner membrane
fusion protein, and AdeC forms the OMP (Nowak et al.,
2015). The over expression of the AdeABC efflux pump can
also grant high-level resistance to carbapenems (in combina-
tion with carbapenem-hydrolyzing oxacillinases) (Perez et al.,
2007). AdeABC is encoded on the chromosome and is nor-
mally regulated by a sensor kinase (AdeS) and a response reg-
ulator (AdeR) (Peleg et al., 2008). A mechanism that regulates
the expression of this pump was illustrated as a two-step regu-
lator (adeR) and sensor (adeS) system; in the adeR or adeS
gene, a single point mutation leads to an amplified expression
and thus to a higher efflux (Perez et al., 2007; Nowak et al.,
2015).
12.2.4. Changes in PBPs
Seven different PBPs (1a, 1c, 2, 3, 4, 4b and 5) in A. baumannii
were found. The resistance of A. baumannii to carbapenems is
related to decreased drug uptake because of porin deficiency,
and diminished affinity for the drug due to modification of
the PBP’s by mutations which is described by a reduced
expression of PBP-2, as shown in isolates from Seville, Spain
(Perez et al., 2007).
12.2.5. Resistance to antibiotics
12.2.5.1. Resistance to aminoglycosides. The presence of genes
coding for aminoglycoside-modifying enzymes (AME) within
class 1 integrons is very frequent in multidrug-resistant A. bau-
mannii isolates. The main classes of enzymes comprising
acetyltransferases, nucleotidyltransferases, and phosphotrans-
ferases have been described (Jung and Park, 2015). It was
lately found that 16S rRNA methylation is mediated by a
recently recognized group of 16S rRNAmethylases-mediated
mechanism of high level of resistance to the parenterally
administered aminoglycosides that are of current clinical use
(Doi and Arakawa, 2007). The responsible genes are mostly
harbored on transposons within transferable plasmids,
enabling them to spread horizontally (Doi and Arakawa,
2007; Jung and Park, 2015). 16S rRNA methylases has been
reported for A. baumannii (armA) strains from Japan, Korea,
and the United States. A new type of AME has been lately dis-
covered and found to play a main role in amikacin resistance
among Acinetobacter spp. in Japan (Perez et al., 2007; Jung
and Park, 2015). Other mechanisms of resistance include alter-
ations in the target ribosomal protein, impaired transport of
aminoglycosides to interior of the bacterial cell, and efflux
pump-mediated removal of aminoglycosides from within the
cell (Jung and Park, 2015).
12.2.5.2. Resistance to quinolones. Alteration in the structure of
DNA gyrase or topoisomerase IV through mutations in the
quinolones resistance-determining regions of the gyrA andPlease cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
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to quinolones. These changes decrease the affinity of the qui-
nolones binding to the enzyme-DNA complex. Another mech-
anism of resistance to the quinolones is caused by efflux
systems that reduce intracellular drug accumulation (Perez
et al., 2007; Potron et al., 2015); comprising RND-type pump
AdeABC and multi antimicrobial extrusion proteinMATE
pump AbeM. Until now, qnr genes and plasmid mediated qui-
nolones resistance has not been reported for A. baumannii
(Potron et al., 2015).
12.2.5.3. Resistance to tetracyclines and glycylcyclines. Two dif-
ferent types of resistance to tetracyclines have been well
explained in A. baumannii. TetA and TetB are specific
transposon-mediated efflux pumps; TetB controls the efflux
of both tetracycline and minocycline, while TetA is only
responsible for the efflux of tetracycline. The second mecha-
nism is the ribosomal protection protein, which protects the
ribosome from the effect of tetracycline. This protein is
encoded by tet(M) gene; it helps in shielding the ribosome from
tetracycline, doxycycline, and minocycline (Perez et al., 2007;
Falagas et al., 2015). Apart from tetracycline-specific efflux
pumps, this class of antimicrobials is also susceptible to efflux
by the multidrug efflux systems, such as the AdeABC pump.
Importantly, tigecycline, which is the first of a new class of
modified tetracycline antimicrobials known as glycylcyclines,
is also a substrate for this emerging efflux system. The function
of the AdeABC efflux pump in diminished susceptibility to
tigecycline was validated by insertional inactivation of the
adeBgene, leading to a major drop in the MIC of tigecycline
(4–0.5 g/ml). These data imply caution when tigecycline treat-
ment for A. baumannii infection is considered in bloodstream
and other sites where drug levels may be suboptimal
(Falagas et al., 2015).
12.2.5.4. Resistance to polymyxin. Polymyxin B and polymyxin
E (colistin, intravenous colistimethate sodium) are peptide
antibiotics that were first isolated in 1947 and have been pro-
gressively used as a ‘‘last-resort” for the treatment of infections
caused by MDR A. baumannii. Unfortunately, resistance to
colistin in A. baumannii has been reported and conceived with
great alarm (Perez et al., 2007). The mechanism of resistance
remains unknown. Reduced binding to the Lipopolysaccharide
(LPS) target site has been shown to cause resistance in E. coli,
Salmonella spp., and Ps. aeruginosa. Furthermore, changes in
OMPs causing lowered susceptibility to polymyxins have been
reported for Ps. aeruginosa. More research is needed to ade-
quately characterize to control infections caused by A.
baumannii.
Determining the geographical dispersion of virulent or
epidemic pathogens is accomplished by identifying and typ-
ing bacteria (Pogue et al., 2015). Molecular typing has a
key role in studying the epidemiology of A. baumannii and
in coping with its epidemic spread. The progress in molecu-
lar typing methods provided the clinical microbiology labo-
ratory with powerful tools, leading to a better
understanding of the epidemiology of bacterial infection
(Pogue et al., 2015). Until now, many molecular techniques
are being used at three different levels to control infections
caused by A. baumannii.l pathogens: Epidemiology and resistance features. Saudi Journal of Biological
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A baumannii is considered by the Infectious Diseases Society of
America as one of the ‘‘red alert” pathogens that significantly
threaten the effectiveness of our current antibacterial arma-
mentarium (Peleg et al., 2008). Unfortunately, as resistance
has increased, a few antimicrobials can be reliably used for
effective treatment of MDR Acinetobacter infections. Since
few antimicrobials remain consistently effective in the treat-
ment of nosocomial Acinetobacter infections, the search for
new drugs and the reevaluation of older agents have become
a priority (Jain and Danziger, 2004).
13.1. Carbapenems
Carbapenems (imipenem and meropenem) resistance Acineto-
bacter is increasingly reported, making MDR Acinetobacter
infections difficult to treat. However, carbapenems continue
to be the treatment of choice in cases where isolates are still
susceptible to this antimicrobial class (Manchanda et al.,
2010).
13.2. Sulbactam
Sulbactam, an inhibitor of b-lactamase, demonstrates in vitro
bactericidal activity against Acinetobacter spp. (Luna and
Aruj, 2007; Dinc et al. 2015) and it is suitable for mild infec-
tions. Several studies illustrate the use of several single agents
in MDR A. baumannii infection therapy. The adequate perfor-
mance (up to 67.5% healing rate) of sulbactam in treating var-
ious types of infections such as meningitis, pneumonia,
peritonitis, surgical site and urinary tract infections, caused
by MDR A. baumannii which also showed resistance to imipe-
nem was further verified by prospective and retrospective set of
patients (Dinc et al. 2015).
13.3. Tigecycline
Tigecycline derivative of minocycline and has bacteriostatic
activity against MDR A. baumannii (Dinc et al., 2015).
High-level resistance to tigecycline has been reported for
some multidrug-resistant A. baumannii isolates, with a con-
cern that this organism can quickly escape this antimicrobial
mediated efflux pumps. Over expression of a multi-drug
efflux pump in A. baumannii isolates with reduced suscepti-
bility to tigecycline has been described (Eliopoulos et al.,
2008).
13.4. Aminoglycosides
Tobramycin and amikacin are some of the aminoglycoside
agents used as therapeutic options in cases of infection
with multidrug-resistant A. baumannii isolates that retain
susceptibility. These options are typically used in combina-
tion with another active antimicrobial agent. Many
multidrug-resistant A. baumannii isolates maintain an inter-
mediate susceptibility to amikacin or tobramycin to which
resistance is highly correlated with aminoglycoside-
modifying enzymes or efflux pump mechanisms (Yadav
et al., 2015).Please cite this article in press as: Almasaudi, S.B. Acinetobacter spp. as nosocomia
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Colistin, a cationic polypeptide, is part of the polymyxin fam-
ily (colistimethate or colistinsulfomethate or polymyxin E) and
is a potent broad-spectrum antimicrobial agent. This agent
was originally used in the 1960 s and 1970 s, but was not pre-
scribed frequently because of concerns with nephrotoxicity and
neurotoxicity (Vourli et al., 2015). Clinicians are going back to
the use of polymyxin B or polymyxin E (colistin) for highly
drug-resistant A. baumannii infections. Observational studies
have shown a rate of 57–77% of cure or improvement among
severely ill patients with multidrug-resistant A. baumannii
infections treated with colistin. These infections included pneu-
monia, bacteremia, sepsis, intra-abdominal, and Central
Nerves System infection (Vourli et al., 2015).
14. Conclusion
Acinetobacter has been known as a major cause of nosocomial
infections worldwide and have shown a broad spectrum of
resistance toward commonly used antimicrobial agents. In
view of this, control measures need to be implemented to con-
trol the spread of this organism in the hospital environment. It
is advisable that healthcare facilities should implement proper
safety programs to limit the spread of these bacteria as well as
other hazardous bacteria. Research should focus on identify-
ing novel agents with lower resistance.
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